has been estimated to exceed $1 billion per year!!. 
Source: GenVec's TNFerade Nears NDA Status (NASDAQ:GNVC) |
"TherAtoh Atonal therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function.
There are currently no effective treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem.
The market potential for this product is truly mammoth, as the cost of medical care for patients with balance disorders has been estimated to exceed $1 billion per year".
Source: GenVec's TNFerade Nears NDA Status (NASDAQ:GNVC) |
"TherAtoh Atonal therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function.
There are currently no effective treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem.
The market potential for this product is truly mammoth, as the cost of medical care for patients with balance disorders has been estimated to exceed $1 billion per year".